OTC Exchange Network Completes Live Test Trade of Fiat and Cryptocurrency
OTC Exchange Network, Inc. ("OTCXN"), a blockchain-powered capital markets infrastructure company, today announced that it completed its first live test trades, which it believes to be the world’s first exchange of tokenized US Dollars and tokenized Bitcoin between two separate trading accounts over an electronic trading platform with assets held in safekeeping at a neutral custodian and digitized on blockchain.
Today, institutional traders conduct block trades of fiat currency and cryptocurrency over e-mail and chat, relying on the reputation and credibility of their counterparties to honor their part of the trades, often taking hours to confirm and settle. The OTCXN platform removes trading counterparty and settlement risk with an atomic exchange of assets on high-performance blockchain and facilitates settlement of transactions instantly, not in hours or days.
Custodians on the OTCXN network use the provided solution to create unique, private blockchain ledgers to represent assets they safekeep on behalf of traders on the OTCXN network. Counterparties’ trades over OTCXN’s block trading platform are enforced by real-time pre-trade credit checks against provable assets on the custodian blockchain ledgers. Trading entities on the OTCXN network use the provided solution to interact directly with the custodian for issuance and redemption of their digital assets. The test trades were conducted using two separate accounts maintained at an escrow services company by OTCXN, one account holding US dollars and the other holding Bitcoin. Volantis Escrow Platform LLC served as the custodian.
“We are profoundly excited to participate in this, the first trade of its kind,” said Barry Thompson, Managing Partner of Volantis Escrow. “We believe that OTCXN’s platform will transform the marketplace, by enabling assured and transparent execution, becoming a trusted cornerstone driving the maturation of the fiat and crypto markets.”
“We believe this is a world first,” said Rosario M. Ingargiola, founder and Chief Executive Officer of OTCXN. “We’ve received dozens of inquiries from trading firms and custodians about our launch date. I’m thrilled that our live test trades were a success and that we’ll soon bring our solution to the market. An independent custodian used OTCXN’s solution for custodians to digitize both fiat and crypto, and these assets were exchanged instantly without trading counterparty or settlement risk.“
OTCXN’s first product delivers end-to-end OTC block trading capabilities for trading fiat vs. crypto, crypto vs. crypto and fiat vs. fiat, all for delivery with instant settlement. OTCXN plans to launch a public beta on July 9, 2018.
OTC Exchange Network (“OTCXN”) is a capital markets infrastructure company using proprietary blockchain technology to eliminate the need for traditional intermediaries and trust between trading counterparties, reducing the risk, friction, and cost of trading. www.otcxn.com @OTCXN
Robert Ferri Partners
Robert Ferri, 415-575-1589
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Vivet Therapeutics Announces 2 Abstracts Accepted for Oral Presentation at 2019 American Society of Gene and Cell Therapy Annual Meeting23.4.2019 08:38:00 CEST | Pressemelding
Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, today announced that new data from its lead development program, VTX-801 a novel investigational gene therapy for WD, and VTX-803, Vivet’ novel therapeutic in development for the treatment of PFIC3, have been accepted for oral presentation during the ASGCT 22nd Annual Meeting, April 29 - May 2, 2019 in Washington, D.C., USA. Dr. Gloria González-Aseguinolaza, Vivet Therapeutics CSO & Head of the Gene Therapy Dept. at FIMA will present data from a recently completed study, validating in WD mice the use of fecal excretion of IV-injected 64copper as a pharmacodynamic endpoint in the VTX-801 Phase I/II trial currently under preparation. These data are the first demonstration of copper homeostasis restoration with 64Copper in an animal model of WD through the delivery of a single, intravenous administration of
Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 201923.4.2019 08:00:00 CEST | Pressemelding
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified 650 V and 900 V gallium nitride (GaN) semiconductors—today shared a glimpse into its 2019 PCIM Europe showcase. Located in Hall 9 Booth 519, it centers on three key points to help conference attendees better understand Transphorm’s high voltage GaN value proposition: Reliability: Design with confidence when using Transphorm’s high quality, high reliability (Q+R) GaN transistors. Drivability: Pair Transphorm’s devices with off-the-shelf drivers, for easing drivability. Simplicity: Experience simpler designs due to minimal external gate drive circuitry along with standard packages, such as TO-220, TO-247, and PQFN, with well-known thermal management techniques. “At PCIM, you’ll see the culmination of Transphorm’s innovation along with its measurable impact on low volume as well as high volume customer applications,” said Philip Zuk, Vice President, Technical Marke
PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC23.4.2019 07:00:00 CEST | Pressemelding
A seminar titled “2H19 PV Market Outlook and Forecast” will be held in Shanghai on June 3, one day prior to SNEC, to discuss global supply chain market outlook in the second half of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005391/en/ 2019 Module Prices and Demand Forecast. (Photo: Business Wire) Held by PV InfoLink, a leading solar market intelligence provider, the seminar will bring together PV manufacturers, developers, EPC, and investors to explore major issues revolving the industry and help participants gain valuable insights for navigating the expanding solar market. PV InfoLink has invited Chinese major companies, including Jinko, Longi, and GCL-Si, to discuss impact of China’s transition to a subsidy-free market. This year, China’s demand will revive later than usual due to policy uncertainty. Moreover, Japan and India, China’s two major trading partners, saw weakening demand after the end of f
JPND Launches Updated Research and Innovation Strategy23.4.2019 06:45:00 CEST | Pressemelding
The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative 1 has launched its updated global Research and Innovation Strategy (RIS) , to provide a unified framework for the support of world class research into neurodegenerative diseases. Neurodegenerative diseases are one of the world’s leading medical and societal challenges and there are now expected to be 50 million people worldwide suffering from Alzheimer’s disease and related disorders. Globally, these numbers show no signs of abating, and it is estimated that by 2050 in Europe alone, the total direct and informal care costs for Alzheimer’s and Parkinson’s disease will exceed €350 billion annually.2 JPND is the first and largest collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases. JPND’s ultimate goal is to accelerate the discovery of a cure and to enable early diagnosis for early personalised treatments. In the meantime, it is essential to implement
Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer22.4.2019 15:00:00 CEST | Pressemelding
Published in Nature Medicine* today, results of WINTHER, the first study pioneered by the WIN Consortium** - - Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone. The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and University of California San Diego, Moores Cancer Center (USA) (Razelle Kurzrock), aimed to expand precision oncology to patients with advanced solid tumors that progressed after treatment with standard therapies. For
PPG Advances Sustainability to Protect and Beautify the World22.4.2019 14:13:00 CEST | Pressemelding
PPG (NYSE:PPG) today published its 2018 Sustainability Report, detailing the company’s performance and progress against its 2025 sustainability goals that contribute to its purpose and promise: WE PROTECT AND BEAUTIFY THE WORLD™. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190422005156/en/ PPG highlights progress against key economic, environment and social goals in its 2018 Sustainability Report. (Graphic: Business Wire) Last year, PPG embedded additional sustainable practices into its operations, introduced new sustainably advantaged products for customers, achieved a record low in injury cases across the company, advanced its global community engagement initiatives, and further advanced its diversity and inclusion efforts. The report is available at sustainability.ppg.com. “Our dedicated workforce continues to drive sustainability deeper into our global operations,” said Michael H. McGarry, PPG chairman and chief execu